Agentic commercial:
AI redefines field, digital and content for precision engagement

Commercial engagement in biopharma was once relatively straightforward, centred on a sales rep speaking directly with a physician, nurse or pharmacist. Today, as therapeutic areas become increasingly specialised, engagement spans territory reps, key account managers, medical science liaisons, brand marketers and service teams. Too often, these functions operate in silos, creating fragmented experiences for healthcare professionals (HCPs), who increasingly expect each interaction to build on the last to deepen their understanding.

At the same time, the customer landscape has expanded to include complex networks of HCPs, patients, health systems and administrators – many of whom are limiting biopharma engagements and turning to AI to guide their decisions. Facing growing clinical complexity alongside restricted HCP access, biopharmas are moving toward more agile and customer-centric commercial models.

To meet these changing expectations, biopharmas are adopting an Agentic Commercial model that brings together AI, field teams, digital engagement and approved content to deliver continuous, personalised experiences for HCPs. Agentic capabilities embedded in industry-specific applications enable teams to capture qualitative real-world insights, identify treatment barriers, provide trusted answers and deliver dynamic content for human and AI-driven engagement. The result is more relevant engagement, better informed HCPs and faster patient access to the right medicines.

An Agentic Commercial model transforms sales teams from promotional distribution channels into strategic sources of customer intelligence, evolving CRM from a system of record into a system of guidance.

Reps conduct nuanced HCP conversations every day, but traditional reporting systems restrict insights capture to rigid picklists and drop-down menus. Critical qualitative context – the ‘why’ behind a physician’s decision or the localised barrier to access – goes unrecorded.

Agentic call reporting uses agentic voice and free-text capabilities, with built-in compliance checks, to help reps capture richer details from HCP conversations. These interactions generate Commercial Evidence – actionable, real-world insights that reveal intent, content gaps and treatment barriers facing physicians and patients.

Commercial leaders gain immediate visibility into real-world friction points. Early implementations show that 65% of Agentic Call Reports identify actionable treatment barriers, enabling field teams and medical specialists to address clinical concerns with precision.

Field teams build trusted human relationships, but they cannot be everywhere at once. Digital channels such as brand websites and email should extend the dialogue and enable more timely responses to questions, yet too often, physicians and patients must navigate websites or lengthy documents to find what they need.

Conversational AI transforms static digital experiences into real-time conversations. Using only medical, legal and regulatory (MLR)-approved content, agents provide trusted, compliant answers to natural language questions in real time.

These interactions also generate valuable Commercial Evidence. Instead of showing only what users clicked, AI reveals what they asked, where they struggled and the information they could not find. Commercial teams can identify content gaps, uncover emerging treatment barriers and trigger timely follow-up from the field. Trusted by eight of the top ten biopharmas, conversational AI drives a 7x lift in high-value actions.

Continuous engagement depends on a steady stream of timely, compliant content. Yet, with global pharma content expenditure reaching $30 billion annually and 29% more assets created year-over-year, content volume is outpacing human review capacity.

In an Agentic Commercial model, accelerating content speed to market is essential. Agentic MLR acts as an end-to-end expert reviewer – understanding document context, mapping specific regulations and executing targeted agent reviews against approved labels, claim libraries and brand SOPs. This shifts human reviewers from line-by-line proofreading to high-impact work.

By accelerating content review while maintaining compliance, commercial teams can respond faster to customer questions across field and digital channels. This delivers a more cost-effective approval process, with content leaders anticipating 38% of the MLR process to be AI-driven by 2028 and targeting a 70%+ reduction in manual review labour.

An Agentic Commercial model enables AI and commercial teams to work together within the same applications, with both operating under shared compliant processes and governance. Agentic capabilities handle repetitive, data-intensive tasks, while humans apply scientific expertise, judgement, strategic action and relationship-building where it matters most.

By connecting AI, field teams, digital engagement and approved content, biopharmas can deliver a personalised, omnichannel customer experience. As therapies become more complex and HCP access more restricted, Agentic Commercial is essential in delivering precision engagement, helping more patients access the right medicines faster.